Tibotec Pharmaceuticals Ltd.

Janssen R&d Ireland

Medivir Ab

Jörg Kurt Wegner

Bart Rudolf Romanie Kesteleyn

Bengt Bertil Samuelsson

Hans Kristian Wallberg

Herman Van Vlijmen

Genadiy Kalayanov

Wim Bert Griet Schepens

Johannes Wilhelmus J Thuring

Kevin Parkes

Carlo Willy Maurice Boutton

HIV inhibitors of formula (I) wherein Ris halo, Calkoxy, trifluoromethoxy; Ris a group of formula (A); Ris a group of formula (B); Ris a group of formula (C); n is 0 or 1; A is CH or N; Rand Rare hydrogen, Callyl, halo; Rand Rare Callyl or Calkoxy-Calkyl; Ris Callyl, cyclopropyl, trifluoromethyl, Calkoxy, or dimethylamino; Ris hydrogen, Calkyl, cyclopropyl, trifluoromethyl, Calkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.

5-amino-4-hydroxypentoyl amides

The present invention relates to methods and systems for predicting the phenotype conferred by a protein. Such methods and systems facilitate the design, optimization, and assessment of the efficiency of a therapeutic regimen based on the genotype of the disease affecting the patient.

Phenotype prediction method

Growing community of inventors

Mechelen, Belgium

Jörg Kurt Wegner